BG61181B1 - Антикоагулантен препарат - Google Patents

Антикоагулантен препарат Download PDF

Info

Publication number
BG61181B1
BG61181B1 BG97199A BG9719992A BG61181B1 BG 61181 B1 BG61181 B1 BG 61181B1 BG 97199 A BG97199 A BG 97199A BG 9719992 A BG9719992 A BG 9719992A BG 61181 B1 BG61181 B1 BG 61181B1
Authority
BG
Bulgaria
Prior art keywords
heparin
epi
protein
administration
administered
Prior art date
Application number
BG97199A
Other languages
Bulgarian (bg)
English (en)
Inventor
Ole J Nordfang
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BG61181B1 publication Critical patent/BG61181B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
BG97199A 1990-06-19 1992-12-18 Антикоагулантен препарат BG61181B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK148890A DK148890D0 (da) 1990-06-19 1990-06-19 Farmaceutisk praeparat
PCT/DK1991/000145 WO1991019514A1 (en) 1990-06-19 1991-05-30 An anticoagulant preparation

Publications (1)

Publication Number Publication Date
BG61181B1 true BG61181B1 (bg) 1997-02-28

Family

ID=8105367

Family Applications (1)

Application Number Title Priority Date Filing Date
BG97199A BG61181B1 (bg) 1990-06-19 1992-12-18 Антикоагулантен препарат

Country Status (11)

Country Link
EP (1) EP0535129B1 (es)
JP (1) JP3362038B2 (es)
AT (1) ATE119781T1 (es)
AU (1) AU645581B2 (es)
BG (1) BG61181B1 (es)
CA (1) CA2085101A1 (es)
DE (1) DE69108242T2 (es)
DK (2) DK148890D0 (es)
ES (1) ES2069894T3 (es)
HU (1) HU221323B1 (es)
WO (1) WO1991019514A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849703A (en) * 1990-08-27 1998-12-15 G. D. Searle & Co. Pre-formed anticoagulant heparin/TFPI complexes
US6291427B1 (en) 1990-08-27 2001-09-18 G.D. Searle & Co. Anticoagulant combination of LACI and sulfated polysaccharides
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5276015A (en) * 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
KR950701820A (ko) * 1992-06-11 1995-05-17 로저 에이. 윌리암스 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)
ZA941414B (en) * 1993-03-02 1994-09-28 Novo Nordisk A G Non-glycosylated TFPI analogues
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
PL374506A1 (en) 2001-10-15 2005-10-31 Chiron Corporation Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0048898B1 (en) * 1980-09-30 1985-04-17 Bayer Ag Method for the production of an antithrombin-heparin complex and pharmaceutical compositions containing the complex
US4689323A (en) * 1983-09-26 1987-08-25 Miles Laboratories, Inc. Covalently bound heparin--antithrombin-III complex
IL79255A0 (en) * 1986-06-26 1986-09-30 Hadassah Med Org Composition for metastasis prevention
US4900723A (en) * 1988-04-29 1990-02-13 E. R. Squibb & Sons, Inc. Method of preventing or reducing venous thrombosis using a thromboxane A2 receptor antagonist in conjunction with heparin and combination
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner

Also Published As

Publication number Publication date
JPH05507926A (ja) 1993-11-11
DE69108242D1 (de) 1995-04-20
HU221323B1 (en) 2002-09-28
EP0535129B1 (en) 1995-03-15
HUT63578A (en) 1993-09-28
AU645581B2 (en) 1994-01-20
DK148890D0 (da) 1990-06-19
AU8060491A (en) 1992-01-07
ES2069894T3 (es) 1995-05-16
ATE119781T1 (de) 1995-04-15
EP0535129A1 (en) 1993-04-07
HU9204036D0 (en) 1993-03-29
WO1991019514A1 (en) 1991-12-26
DK0535129T3 (da) 1995-08-07
DE69108242T2 (de) 1995-07-06
CA2085101A1 (en) 1991-12-20
JP3362038B2 (ja) 2003-01-07

Similar Documents

Publication Publication Date Title
EP1359222B1 (en) Hybrid human/porcine factor VIII
US6624141B1 (en) Protamine fragment compositions and methods of use
KR100366982B1 (ko) 혈전용해활성단백질및항응고제의조합물,및그의용도
RU2127600C1 (ru) Фармацевтический препарат, обладающий свойством ускорять процесс коагуляции крови, способ ускорения коагуляции крови in vitro и применение ингибитора epi активности в качестве вещества, обладающего свойством ускорять процесс коагуляции крови
Uchiba et al. Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats
US20130064807A1 (en) Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors
EP0255206A2 (en) Peptides that inhibit von Willebrand factor binding
EP0535129B1 (en) An anticoagulant preparation
US20080293628A1 (en) Methods and Compositions for the Inhibition of Thrombus Formation
Mattsson et al. Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro
GIERCKSKY et al. The effect of intravenous injection of purified human tissue thromboplastin in rats
Jackson et al. Antithrombotic effects of hirulog in a rat carotid endarterectomy model
JPH11507664A (ja) 第ｖｉｉｉ因子由来の第ｉｘ因子結合ペプチド及び血液凝固のインヒビターとしてのそれらの使用
US5804181A (en) Pharmaceutical preparation for the prevention and treatment of blood coagulation disorders
EP0239644A1 (en) Novel physiologically active substance having blood coagulation controlling activity
WO2010083320A2 (en) Methods and compositions for the inhibition of thrombus formation
US7977460B2 (en) Compositions comprising coagulation factors IXA and VIII for the treatment of haemophilia A or B
Worowski The hypercoagulability in mercury chloride intoxicated dogs
EP0515550B1 (en) Heparin neutralization with platelet factor 4
Ul'yanov et al. Antidiabetic and anticoagulant properties of heparin–glutamic acid complex
TW202146042A (zh) 用於治療動脈和靜脈血栓形成的協同且靶向的組成物
US20200054719A1 (en) E-we thrombin analog and fibrinolytic combination
Sasaki et al. Neutralization of DHG, a new depolymerized holothurian glycosaminoglycan, by protamine sulfate and platelet factor 4
McIntosh Investigations of the thrombin generation test for the measurement of factor VIII
KR20020092469A (ko) 인자 ＶＩＩａ 및 인자 ＸＩＩＩ를 포함하는 제약학적조성물